NON-COMPETITION AGREEMENTNon-Competition Agreement • December 29th, 2010 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations • Maryland
This NON-COMPETITION AGREEMENT (this “Agreement”) is dated as of December 23, 2010, by and among Dr. Ryuji Ueno, as trustee of the Ryuji Ueno Revocable Trust under Trust Agreement dated December 20, 2002 (the “Ueno Trust”), and Dr. Sachiko Kuno as trustee of the Sachiko Kuno Revocable Trust under Trust Agreement dated December 20, 2002 (the “Kuno Trust”) (each a “Shareholder” and collectively, the “Shareholders”), Dr. Ryuji Ueno, an individual (“Ueno”), and Dr. Sachiko Kuno, an individual (“Kuno” and collectively with Ueno, the “Principals” and together with the Shareholders, each a “Seller” and collectively, the “Sellers”), and Ambrent Investments S.à r.l., a company organized under the laws of Luxembourg (the “Purchaser”), and Sucampo Pharmaceuticals, Inc., a Delaware corporation (the “Parent”). Any capitalized terms used but not defined in this Agreement have the respective meanings set forth in the SPA (as defined below).
STOCK PURCHASE AGREEMENT BY AND AMONG SUCAMPO PHARMACEUTICALS, INC., AMBRENT INVESTMENTS S.À R.L., RYUJI UENO, AS TRUSTEE OF THE RYUJI UENO REVOCABLE TRUST UNDER TRUST AGREEMENT DATED DECEMBER 20, 2002, SACHIKO KUNO, AS TRUSTEE OF THE SACHIKO KUNO...Stock Purchase Agreement • December 29th, 2010 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of December 23, 2010, is made by and among Dr. Ryuji Ueno, as trustee of the Ryuji Ueno Revocable Trust under Trust Agreement dated December 20, 2002 (the “Ueno Trust”), and Dr. Sachiko Kuno as trustee of the Sachiko Kuno Revocable Trust under Trust Agreement dated December 20, 2002 (the “Kuno Trust”) (each a “Shareholder” and collectively, the “Shareholders”), Dr. Ryuji Ueno, an individual (“Ueno”), and Dr. Sachiko Kuno, an individual (“Kuno” and collectively with Ueno, the “Principals” and together with the Shareholders, each a “Seller” and collectively, the “Sellers”), Ambrent Investments S.à r.l., a company organized under the laws of Luxembourg, with registered office at 46A, Avenue J.F. Kennedy, L-1855 Luxembourg, Luxembourg (“Purchaser”), and Sucampo Pharmaceuticals, Inc., a Delaware corporation (“Parent”). Certain capitalized terms used in this Agreement are defined in Section 9.9 hereof.
